Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies

作者
Sherry L. LaPorte,Daniel R. Hostetter,Laurie Wong,Jennifer Razo,Linnea Diep,Clayton W. White,Jennifer Hope Richardson,W. Michael Kavanaugh,Bryan A. Irving
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:14 (12_Supplement_2): A203-A203 被引量:4
标识
DOI:10.1158/1535-7163.targ-15-a203
摘要

Abstract T cell-engaging bispecific antibodies (TCBs) represent a highly potent modality to direct the activity of cytotoxic T cells to tumors. TCBs are designed to bind both a surface tumor antigen and the CD3ϵ subunit of the T cell receptor, thereby enabling T cells to kill tumor cells. Because T cell bispecifics bypass TCR antigen recognition and co-stimulatory requirements for T cell activation, they obviate the need for tumor-specific immunity and overcome many impediments faced by T cells in the tumor-microenvironment. TCBs have shown clinical activity in hematologic malignancies as evidenced by the recent approval of blinatumomab for the treatment of relapsed refractory acute lymphoblastic leukemia based on its ability to direct T cells against CD19+ cells. Development of TCBs for non-hematologic cancers is proving more challenging, however, due to the high potency of the modality and its inability to discriminate between cells expressing target antigen in the tumor and those in healthy tissue. Because antigens with highly restricted tumor expression are rare, toxicity directed against healthy tissues has limited the therapeutic utility of TCBs for most solid tumor targets. In addition, because TCBs are administered at very low doses, preferential distribution to circulating T cells or to healthy tissues can limit drug exposure in tumors. Therefore new methods are needed that enable the potent anti-tumor activity of TCBs without on-target damage to normal tissues. Here we describe a T cell-engaging Bispecific Probody therapeutic (TCBP) targeting CD3 and Epidermal Growth Factor Receptor (EGFR). Probody therapeutics are recombinant, proteolytically-activated antibody prodrugs designed to widen therapeutic window by minimizing interaction with normal tissues and maximizing interactions with tumors. A Probody therapeutic is an antibody in which the antigen-binding site is blocked by a masking peptide extension from the amino terminus of the light chain. The peptide mask, joined to the antibody by a protease-cleavable linker, can be removed by proteases that are more active in the tumor microenvironment than in normal tissue, allowing for tumor-localized activity. We have previously demonstrated that an EGFR-targeted Probody therapeutic limits interaction with EGFR-expressing tissue while preserving anti-tumor activity. To demonstrate that Probody technology can address the limitations of bispecific antibodies, we compared CD3-EGFR TCBPs to the corresponding unmasked TCB for their ability to direct T cell-mediated cytotoxicity of EGFR+ tumor cells in vitro. While the unmasked CD3-EGFR TCB demonstrated potent T cell- and EGFR-dependent killing at single-digit pM concentrations, the CD3-EGFR TCBP exhibited reduced targeted cytotoxicity by up to 3000-fold. In a tumor model utilizing engraftment of human T cells in NSG mice, both TCB Probody therapeutic and its parental TCB effectively eliminated established EGFR+ HT-29 colorectal tumors at equivalent doses. In contrast, an ongoing study in non-human primates has shown at least a 10-fold higher maximum tolerated dose for the CD3-EGFR TCBP relative to its corresponding CD3-EGFR TCB. As a result, Probody technology has the potential to increase therapeutic window and may enable potent bispecific therapies for solid tumors that are limited by on-target toxicities in healthy tissue. Citation Format: Sherry L. LaPorte, Daniel R. Hostetter, Laurie Wong, Jennifer Razo, Linnea Diep, Clayton W. White, Jennifer H. Richardson, W. Michael Kavanaugh, Bryan A. Irving. CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A203.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Miianlli发布了新的文献求助10
刚刚
1秒前
余香的应助被大碗宽面采纳,获得10
2秒前
小写发布了新的文献求助10
2秒前
单薄黎云完成签到,获得积分10
2秒前
小雨发布了新的文献求助10
2秒前
慕青的应助被风趣的胜采纳,获得10
3秒前
3秒前
3秒前
3秒前
5秒前
Rider发布了新的社区帖子
5秒前
星辰大海的应助被Yilo采纳,获得10
6秒前
天天快乐的应助被hyfaie采纳,获得10
6秒前
科研通AI6.4的应助被renn采纳,获得10
6秒前
zhhyi1976完成签到,获得积分10
6秒前
充电宝的应助被liwenhao采纳,获得10
6秒前
澄黄澄完成签到,获得积分10
7秒前
敏感墨镜发布了新的文献求助10
8秒前
li的应助被alpv采纳,获得10
8秒前
10秒前
10秒前
lilili完成签到,获得积分10
10秒前
10秒前
开花发布了新的文献求助10
10秒前
火火发布了新的文献求助10
11秒前
无极微光的应助被12345678采纳,获得20
11秒前
大帅Enlly完成签到,获得积分10
11秒前
12秒前
独特的千青完成签到,获得积分10
13秒前
tonny发布了新的文献求助10
13秒前
14秒前
大帅Enlly发布了新的文献求助10
14秒前
14秒前
15秒前
15秒前
脑斧儿完成签到,获得积分10
16秒前
风趣的胜发布了新的文献求助10
17秒前
鲤鱼从安完成签到,获得积分10
17秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184061
求助须知:如何正确求助?哪些是违规求助? 9573151
关于积分的说明 21829878
捐赠科研通 7781058
什么是DOI,文献DOI怎么找? 3434216
关于科研通互助平台的介绍 2558337
邀请新用户注册赠送积分活动 2480674